The therapeutic effects on the Lyn-deficient mouse SLE model obtained by the genetic approach (deletion of Irf5 after the disease onset) next prompted us to develop IRF5 inhibitors as novel therapeutics for SLE. The gene discussed is LYN; the disease is systemic lupus erythematosus.